[go: up one dir, main page]

FI963164L - Diabeteksen vastaisia peptidejä ja menetelmä - Google Patents

Diabeteksen vastaisia peptidejä ja menetelmä Download PDF

Info

Publication number
FI963164L
FI963164L FI963164A FI963164A FI963164L FI 963164 L FI963164 L FI 963164L FI 963164 A FI963164 A FI 963164A FI 963164 A FI963164 A FI 963164A FI 963164 L FI963164 L FI 963164L
Authority
FI
Finland
Prior art keywords
antidiabetic
peptides
antidiabetic peptides
Prior art date
Application number
FI963164A
Other languages
English (en)
Swedish (sv)
Other versions
FI963164A0 (fi
Inventor
Richard J Albertini
Michael T Falta
Original Assignee
Univ Vermont
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Vermont filed Critical Univ Vermont
Publication of FI963164A0 publication Critical patent/FI963164A0/fi
Publication of FI963164L publication Critical patent/FI963164L/fi

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503Immunoglobulin superfamily
    • C07K14/7051T-cell receptor (TcR)-CD3 complex
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • C07K16/4241Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig
    • C07K16/4258Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig against anti-receptor Ig
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5094Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for blood cell populations
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966Animal cells
    • G01N33/56972White blood cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53DNA (RNA) vaccination
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pathology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Virology (AREA)
FI963164A 1994-02-14 1996-08-13 Diabeteksen vastaisia peptidejä ja menetelmä FI963164L (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/195,963 US6113903A (en) 1989-03-21 1994-02-14 Peptides and methods against diabetes
PCT/US1995/001572 WO1995021623A1 (en) 1994-02-14 1995-02-10 Peptides and methods against diabetes

Publications (2)

Publication Number Publication Date
FI963164A0 FI963164A0 (fi) 1996-08-13
FI963164L true FI963164L (fi) 1996-10-07

Family

ID=22723558

Family Applications (1)

Application Number Title Priority Date Filing Date
FI963164A FI963164L (fi) 1994-02-14 1996-08-13 Diabeteksen vastaisia peptidejä ja menetelmä

Country Status (10)

Country Link
US (1) US6113903A (fi)
EP (1) EP0744956A1 (fi)
JP (1) JPH10501210A (fi)
KR (1) KR100280220B1 (fi)
AU (1) AU690234B2 (fi)
CA (1) CA2182978A1 (fi)
FI (1) FI963164L (fi)
NO (1) NO963366L (fi)
NZ (1) NZ282118A (fi)
WO (1) WO1995021623A1 (fi)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997008303A1 (en) * 1995-08-30 1997-03-06 University Technologies International Inc. Transgenic animals expressing diabetogenic t-cell receptor transgenes
US6054292A (en) * 1997-07-18 2000-04-25 Incyte Pharmaceuticals, Inc. T-cell receptor protein
AU5984701A (en) * 2000-05-12 2001-11-20 Univ Oregon Health & Science Method of treating immune pathologies with low dose estrogen
US7462486B2 (en) * 2000-05-12 2008-12-09 Oregon Health & Science University Methods of selecting T cell receptor V peptides for therapeutic use
US7790690B2 (en) 2000-10-11 2010-09-07 U.S. Department Of Veterans Affairs Glucose sensitive regulator of insulin transcription
US20030100056A1 (en) * 2000-12-22 2003-05-29 Anneli Attersand Protein cluster II
EP1786465A4 (en) * 2004-07-30 2009-01-21 Univ Oregon Health & Science METHODS FOR DETECTION AND TREATMENT OF AUTOIMMUNE DISORDERS
US7375211B2 (en) * 2005-11-18 2008-05-20 Kou Zhong C Method for detection and quantification of T-cell receptor Vβ repertoire

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4066510A (en) * 1976-05-24 1978-01-03 Massachusetts Institute Of Technology Assay for mutagenesis in diploid human lymphoblasts
US4544632A (en) * 1981-06-12 1985-10-01 Yuichi Yamamura Human T cell lines and method of producing same
US4647535A (en) * 1981-08-12 1987-03-03 Research Corporation Human nonsecretory plasmacytoid cell line
US4886743A (en) * 1985-04-24 1989-12-12 California Institute Of Technology Diagnostic reagents based on unique sequences within the variable region of the T cell receptor and uses thereof
EP0616811A1 (en) * 1985-12-03 1994-09-28 T Cell Sciences, Inc. Cell-free T cell antigen receptor and its clinical utilities
US5112735A (en) * 1987-06-22 1992-05-12 University Of Vermont Detection of lymphocyte amplification
WO1989006968A1 (en) * 1988-02-03 1989-08-10 Xoma Corporation Therapeutic use of anti-t cell immunotoxin for autoimmune diseases
FI891226L (fi) * 1988-04-28 1989-10-29 Univ Leland Stanford Junior Reseptordeterminanter i anti-t-celler foer behandling av autoimmunsjukdom.
US5612035A (en) * 1989-03-21 1997-03-18 The Immune Response Corporation Vaccination against diseases resulting from pathogenic responses by specific T cell populations
CA2064077C (en) * 1989-07-19 2002-03-12 Arthur A. Vandenbark T cell receptor peptides as therapeutics for autoimmune and malignant disease
US5614192A (en) * 1989-07-19 1997-03-25 Connective Therapeutics, Inc. T cell receptor peptides as therapeutics for immune-related disease
IL99699A (en) * 1990-10-10 2002-04-21 Autoimmune Inc Drug with the option of oral, intra-intestinal, or inhaled dosing for suppression of autoimmune response associated with type I diabetes
JPH06507384A (ja) * 1991-01-22 1994-08-25 ザ イミューン レスポンス コーポレイション 特定のt細胞群による病理的応答により生じる疾患に対するワクチン投与および方法
US5552300A (en) * 1994-01-13 1996-09-03 T Cell Sciences, Inc. T cell antigen receptor V region proteins and methods of preparation thereof

Also Published As

Publication number Publication date
WO1995021623A1 (en) 1995-08-17
AU690234B2 (en) 1998-04-23
NZ282118A (en) 1998-06-26
FI963164A0 (fi) 1996-08-13
EP0744956A1 (en) 1996-12-04
JPH10501210A (ja) 1998-02-03
AU1912895A (en) 1995-08-29
KR100280220B1 (ko) 2001-02-01
NO963366L (no) 1996-10-14
NO963366D0 (no) 1996-08-13
US6113903A (en) 2000-09-05
CA2182978A1 (en) 1995-08-17

Similar Documents

Publication Publication Date Title
BR9503005A (pt) Pneumático e compósito
DE69524542D1 (de) Farbkorrekturverfahren und -vorrichtung
FI974494L (fi) Paikannusmenetelmä ja paikannusjärjestely
KR960704093A (ko) 전극 및 이의 제조방법(electrode and preparation thereof)
FI965225L (fi) Uusia peptidejä
FI954980L (fi) Liitosnauha, liitosmenetelmä ja liitosnauhan käsittävä liitos
FI960888L (fi) Protokadheriiniproteiineja ja niiden käyttö
FI961350L (fi) Hapteenimerkityt peptidit
BR9506832A (pt) N-pirazolilanilinas e n-pirazolilaminopiridinas
DE69529223D1 (de) Prüfverfahren
IS4459A (is) Ný peptíð er hafa ónæmisbreytandi áhrif
FI971884A0 (fi) Tietoliikennemenetelmä ja -järjestely
US5547381B1 (en) Fangs and application thereof
FI954499L (fi) Menetelmä ja analyysi
FI951101L (fi) 5-vinyyli- ja 5-etinyylikinoloni- ja -naftyridonikarboksyylihapot
DE69420720D1 (de) Federspeicherbremszylinder und montageverfahren dafür
FI970168A0 (fi) Peptidejä
FI964267A (fi) Porfosyaniini ja CNC-laajennetut porfyriinit
FI942298A0 (fi) Menetelmä ja sovitelma tilaelementtien siirtämiseksi
FI963164L (fi) Diabeteksen vastaisia peptidejä ja menetelmä
FI964363L (fi) Peptidejä
FI972551L (fi) Päällystyslaite ja menetelmä sitä varten
FI962836L (fi) Psoriasiksen vastaisia peptidejä ja menetelmiä
FI960706L (fi) Uusi proteiini ja menetelmiä proteiinin valmistamiseksi
GB9423372D0 (en) Proteins and their uses